Evaluating the effect of Phyllanthus Emblica, Rosa Damascene, Marshmallow and Honey on COVID 19

INTERVENTION: Intervention 1: Intervention group: patients will receive the main drug after treatment with routine medications. Each package of medicine contains 180 grams of medicine, which consists of a combination of 30 grams of Phyllanthus Emblica (Amla), 20 grams of Rosa Damascene (Rose), 20 grams of Althaea Officinalis (marshmallow) powder, which is well powdered and mixed with110 grams of Honey. Patients should eat 4 grams of the drug every 6 hours for 10 days. Intervention 2: Control group: After being treated with routine medications. They will be treated with placebo. The contents of each placebo package include 90 grams of starch powder and 90 grams of sugar syrup, which is completely similar to the main drug with its natural and allowable color. Patients should take 4 grams of the drug every 6 hours every 10 days. CONDITION: COVID 19. ; Corona virus infection, unspecified U07.1 PRIMARY OUTCOME: Viral diagnostic test. Timepoint: The first day of the study and the end of the study. Method of measurement: Polymerase chain reaction. SECONDARY OUTCOME: Body Pain. Timepoint: Daily. Method of measurement: Patients interview and patient file. C_reactive protein. Timepoint: The first day of the study and the end of the. Method of measurement: Agglutination Kit. Chest CT Scan. Timepoint: The first day of the study and the end of the study. Method of measurement: CT scan set. Chill. Timepoint: Daily. Method of measurement: Patients interview and patient file. Cough. Timepoint: Daily. Method of measurement: Patients interview and patient file. Dyspnea. Timepoint: Daily. Method of measurement: Patients interview and patient file. Erythrocyte sedimentation Rate. Timepoint: The first day of the study and the end of the study. Method of measurement: Wester Green. Fever. Timepoint: Daily. Method of measurement: Thermometer. Lymphocyte blood count. Timepoint: The first day of the study and the end of the. Method of measurement: Cell counter. Neutrophyle blood count. Timepoint: The first day of the study and the end of the study. Method of measurement: Cell counter. Platelet. Timepoint: The first day of the study and the end of the study. Method of measurement: Cell counter. Respiratory Rate. Timepoint: Daily. Method of measurement: Patients interview and patient file. Weakness. Timepoint: Daily. Method of measurement: Patients interview and patient file. INCLUSION CRITERIA: Age =18 years Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19 Lung involvement confirmed with chest imaging Hospitalized with: Fever or Respiratory rate >24/min Or Cough Less than 8 days since illness onset Willingness of study participant to accept randomization to any assigned treatment arm Acceptance of non‐participation in another study before the 28th day of the study